ALB and morbid obesity: The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline suggested that patients with IMN and NS, with marked reduction in serum albumin (<25 g/l) and additional risks for thrombosis (e.g., congestive heart failure; prolonged immobilization; morbid obesity; abdominal, orthopedic, or gynecologic surgery), were considered for prophylactic anticoagulant therapy, using oral warfarin (Grade 2 C) [14].